NCT03208166

Brief Summary

The purpose of this study is to determine the effects of the Doctormate device, a specialized blood pressure cuff used to perform remote limb ischemic conditioning, on cerebral blood flow in subjects with intracranial atherosclerosis. Previous studies in patients with narrowing of the brain arteries have shown that this device is safe to use and suggested that if this device is inflated in both arms for 5 minutes, followed by deflation for 5 minutes and repeated 4 times in a row every day for 6-9 months, the risk of another stroke is lowered and the device may increase the blood flow to the brain.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 15, 2017

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

June 30, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 5, 2017

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2018

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

October 7, 2019

Completed
Last Updated

October 7, 2019

Status Verified

September 1, 2019

Enrollment Period

12 months

First QC Date

June 30, 2017

Results QC Date

September 13, 2019

Last Update Submit

September 13, 2019

Conditions

Outcome Measures

Primary Outcomes (2)

  • Percent Change in Cerebral Blood Flow (CBF)

    Percent change CBF from baseline to 30 days as determined by ASL MRI imaging.

    Baseline and 30 days

  • Change in Putative Blood Biomarkers

    Change in the absolute levels of the following biomarkers will be measured from baseline to 30 days: Nitrite, IL-10, SDF1, Micro RNA 144. Lp-PLA2, IL-6. hsCRP, Soluble E selectin, ICAm, MMP-9, PAI-1,tPA, ADMA

    30 days

Study Arms (2)

Ischemic Conditioning

EXPERIMENTAL

Doctormate device is used daily.

Device: DoctormateOther: Usual Care

Usual Care

OTHER

Standard medical care.

Other: Usual Care

Interventions

Ischemic conditioning device

Ischemic Conditioning

Standard medical care

Ischemic ConditioningUsual Care

Eligibility Criteria

Age30 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Symptomatic cerebral infarction within 30 days of enrollment attributed to 70-99% stenosis of a major intracranial artery (carotid artery, MCA stem (M1), vertebral artery, or basilar artery) that is documented by any of the following: MRA, CTA, or catheter angiography. Percent stenosis will be measured according to WASID criteria (= 1 - \[Ds / Dn\]) x 100% with Ds \[diameter of stenosis\] and Dn \[diameter of normal vessel\]).19
  • Modified Rankin score of ≤ 3
  • Age ≥ 30 years and ≤ 90 years. Subjects 30-49 years are required to meet at least one additional criteria (i-vi) provided in the table below to qualify for the study. This additional requirement is to increase the likelihood that the symptomatic intracranial stenosis in subjects 30-49 years is atherosclerotic.
  • i. insulin dependent diabetes for at least 15 years
  • ii. at least 2 of the following atherosclerotic risk factors: hypertension (BP \> 140/90 or on antihypertensive therapy); dyslipidemia (LDL \> 130 mg /dl or HDL \< 40 mg/dl or fasting triglycerides \> 150 mg/dl or on lipid lowering therapy); smoking; non-insulin dependent diabetes or insulin dependent diabetes of less than 15 years duration; family history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, stroke, carotid endarterectomy or stenting, peripheral vascular surgery in parent or sibling who was \< 55 years of age for men or \< 65 for women at the time of the event
  • iii. history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, carotid endarterectomy or stenting, or peripheral vascular surgery for atherosclerotic disease
  • iv. any stenosis of an extracranial carotid or vertebral artery, another intracranial artery, subclavian artery, coronary artery, iliac or femoral artery, other lower or upper extremity artery, mesenteric artery, or renal artery that was documented by non-invasive vascular imaging or catheter angiography and is considered atherosclerotic
  • v. aortic arch atheroma documented by non-invasive vascular imaging or catheter angiography
  • vi. any aortic aneurysm documented by non-invasive vascular imaging or catheter angiography that is considered atherosclerotic
  • Recent (within 30 days) negative pregnancy test in a female who has had any menses in the last 12 months
  • Subject is willing and able to return in 30 days for close-out visit for the study
  • Subject is available by phone
  • Subject is able to apply the conditioning device or has access to another person (family member, friend) who can assist with application of conditioning device if needed
  • Subject understands the purpose and requirements of the study, can make him/herself understood, and has provided informed consent
  • Subject is able to undergo brain MRI

You may not qualify if:

  • Previous treatment of target lesion with a stent, angioplasty, or other mechanical device, or plan to perform one of these procedures
  • Plan to perform concomitant angioplasty or stenting of an extracranial vessel tandem to an intracranial stenosis
  • Intracranial tumor (except meningioma) or any intracranial vascular malformation
  • Thrombolytic therapy within 24 hours prior to enrollment
  • Progressive neurological signs within 24 hours prior to enrollment
  • Any intracranial hemorrhage (parenchmal, subarachnoid, subdural, epidural) within 90 days
  • Any untreated chronic subdural hematoma
  • Intracranial arterial stenosis due to arterial dissection, Moya Moya disease; any known vasculitic disease; herpes zoster, varicella zoster or other viral vasculopathy; neurosyphilis; any other intracranial infection; any intracranial stenosis associated with CSF pleocytosis; radiation induced vasculopathy; fibromuscular dysplasia; sickle cell disease; neurofibromatosis; benign angiopathy of central nervous system; post-partum angiopathy; suspected vasospastic process, suspected recanalized embolus
  • Presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal atrial fibrillation, mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within three months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction less than 30%
  • History of upper extremity ischemia, known subclavian or brachial artery stenosis, subclavian steal syndrome, any upper extremity soft tissue, orthopedic or vascular injury, or mastectomy or other procedure that may contraindicate taking blood pressure or having a cuff on the arm for the conditioning treatment
  • Difference in systolic blood pressure of \> 15 mm Hg between both arms
  • Known allergy to aspirin or clopidogrel
  • Active peptic ulcer disease, major systemic hemorrhage within 30 days, active bleeding diathesis, platelets \< 100,000, hematocrit \< 30, INR \> 1.5, clotting factor abnormality that increases the risk of bleeding, current alcohol or substance abuse, uncontrolled severe hypertension (systolic pressure \> 180 mm Hg or diastolic pressure \> 115 mm Hg), severe liver impairment (AST or ALT \> 3 x normal, cirrhosis), subject on dialysis
  • Major surgery (including open femoral, aortic, or carotid surgery, cardiac) within previous 30 days or planned in the next 30 days after enrollment
  • Indication for warfarin or heparin beyond enrollment (NOTE: exceptions allowed for subcutaneous heparin for deep vein thrombosis (DVT) prophylaxis while hospitalized)
  • +7 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of South Carolina

Charleston, South Carolina, 29403, United States

Location

MeSH Terms

Conditions

Intracranial Arteriosclerosis

Condition Hierarchy (Ancestors)

Intracranial Arterial DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular Diseases

Limitations and Caveats

Study was stopped early because of low recruitment rate

Results Point of Contact

Title
Marc Chimowitz, MD
Organization
Medical University of South Carolina

Study Officials

  • Marc I Chimowitz, MD

    Medical University of South Carolina

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 30, 2017

First Posted

July 5, 2017

Study Start

June 15, 2017

Primary Completion

May 30, 2018

Study Completion

May 30, 2018

Last Updated

October 7, 2019

Results First Posted

October 7, 2019

Record last verified: 2019-09

Data Sharing

IPD Sharing
Will not share

Locations